Safety study of a test system for Loargys-treated patients
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study evaluates whether a new test system is safe to use in patients who are already taking Loargys (a medicine for a rare condition called ARG1-D, which affects how the body processes a protein building block called arginine). The study simply observes how the test system works in people already on this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must currently be taking Loargys medicine for ARG1-D
- You must be willing to sign an informed consent form (a document stating you understand the study and agree to participate)
- No other medical conditions will disqualify you from this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether replacing the body’s arginine (an amino acid) can improve outcomes for children and young adults hospitalized with COVID-19. It may help the immune response, but you must meet several safety criteria to join.
This trial tests a new drug called ARGX-124 in healthy people to see if it is safe. It is a first step before testing it in patients with certain conditions.
This study follows people who have (or might have) NAGS deficiency and who are taking Carbaglu to treat it. The goal is to better track safety and health outcomes over time.
This trial tests whether taking an amino acid supplement called L-arginine every day can improve how the body controls blood sugar and uses insulin. It may help people with prediabetes or metabolic syndrome lower their risk of developing type 2 diabetes.
This study tests a new experimental drug called PG-033 in healthy adults. It helps doctors find out if the drug is safe and how your body processes it at different dose levels.
This early-stage study tests a new experimental drug called LG-0317 in healthy volunteers to see if it is safe and how the body processes it. If you are healthy and meet the basic requirements, this trial may help advance a new treatment option.
Hear when a new ARG1 Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.